© Copyright 2017 Sense Biodetection Limited. Company Registration: 08624309. All rights reserved.
Jeff Warren is a serial MedTech and Biotech angel investor and an experienced board director in a range of sectors, including life sciences.
He has 30 years' financial management experience, including high level corporate governance and regulatory environment experience. He held the post of CFO of Bristol & West Building Society from 1992. Following the acquisition of Bristol & West by Bank of Ireland, he was appointed CEO of Bristol & West PLC in 1999, and subsequently also took responsibility for the Bank of Ireland UK Branch network.
In his role as Chairman Jeff brings extensive knowledge and experience of growing companies in this dynamic market sector.
Peter Dines is Head of Life Sciences and Investment Director at Mercia Technologies PLC and Mercia Fund Management.
He a highly successful entrepreneur and investor with 20 years' experience in the healthcare sector, holding numerous directorships across a wide range of life sciences businesses.
Over his career he has been involved with a number of high profile turnarounds and exits within the sector, including the acquisition of Surgicraft's loss making business where, as Managing Director, sales quadrupled within three years and the business was subsequently sold to ISIS Equity Partners.
Peter's track record of commercial success and wide ranging knowledge of the sector bring invaluable insight to Sense.
Harry has extensive experience in the management of high growth businesses in the life sciences field, having held a number of senior roles in start-up companies.
In addition to his position at SENSE, he is also the Research Development Director at Imperial College’s Institute of Biomedical Engineering, where he coordinates multidisciplinary research initiatives in the medical technology field, promoting translation through collaboration with clinical investigators, Imperial Innovations and Med-Tech companies.
Previously, Harry was Director of Business Development and Company Secretary at Oxford BioTherapeutics, an emerging biotech company located in Oxford, UK and San Jose, CA, focussed on cancer target / biomarker discovery and the development of novel antibody-based drugs for cancer. During five years at the company he completed numerous major collaboration and licensing agreements with global biopharmaceutical and diagnostics companies (including GSK, Sanofi, Amgen, BMS, Seattle Genetics, Alere & Menarini).
In his earlier career as a research scientist, Harry completed a PhD and post-doctoral research on the industrial application of thermostable enzymes at the University of Bath and worked for companies in the fields of genomics, biomanufacturing and scientific software development. Harry has an MBA from Cranfield School of Management.
Ralph has over 15 years experience of the design, development and manufacture of medical devices both in industry and through consulting to some of the worlds leading pharmaceutical and diagnostic companies. He is a degree qualified designer and engineer and has managed development programmes across many areas of the medical device industry.
He was formerly Head of Development at a startup company manufacturing novel drug delivery devices. Here he ran the engineering team and led the successful design and development of a number of products in a role overseeing both internal and key client projects.
His recent experience includes working as a Senior Consultant in the Medical Technology Division of world leading product development specialists Cambridge Consultants.
Through these roles he has developed a proven track record of creating novel intellectual property as well as extensive experience of managing teams through product development and transfer to manufacture, he also has a wide ranging knowledge of industry regulation and ISO 13485 compliant quality systems.
As CDO he is responsible for overseeing the development of Sense’s commercial product range.
Chief Executive Officer
Chief Development Officer